Can rituximab cause hyperthyroidism?

Rituximab, a chimeric monoclonal antibody against CD20-positive B lymphocytes, is known to decrease synovial lymphocyte aggregates in patients with RA. Our hypothyroid diabetic patient with RA developed hyperthyroidism 4 months after initiating rituximab therapy.

What is the best definitive treatment for Graves disease?

Radioactive iodine. The most commonly used therapy for Graves disease is radioactive iodine. Indications for radioactive iodine over antithyroid agents include a large thyroid gland, multiple symptoms of thyrotoxicosis, high levels of thyroxine, and high titers of TSI.

Are there any new treatments for Graves disease?

In January of 2020, Teprotumumab was approved by the FDA for the treatment of TED in Graves’ Disease patients. Teprotumumab is a human-derived monoclonal antibody against IGF1-R, effectively blocking the inflammatory responses of IGF1-R on orbital fibroblasts and reducing the effects of TED.

What kind of cancer can rituximab be used for?

Rituximab is FDA approved for the treatment of low-grade or follicular CD20-positive, B-cell non-Hodgkin’s lymphoma (NHL); treatment of diffuse large B-cell CD20-positive NHL; treatment of rheumatoid arthritis (RA) in combination with methotrexate. Rituximab has not been approved for any neurologic use.

What is the clinical response rate for rituximab?

A shorter disease duration was associated with a better clinical response to rituximab (odds ratio 0.81, P = 0.025) and the response rate was better (P = 0.05) in common forms (83.3%) than in sensory forms (42.9%). No major adverse events were recorded. Rituximab is efficacious in CIDP patients with haematological or autoimmune disease.

Are there any clinical studies for rituximab in CIDP?

We aimed to analyse the response to rituximab in a cohort of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) patients with associated disorders. We conducted a clinical and electrophysiological retrospective monocentric study in 28 CIDP patients.

Is it safe to take Rituximab for MN?

Marco et al confirmed that treatment with rituximab (in 13 patients as first-line therapy, in the remaining 25 after conventional immunosuppressive therapy) was remarkably safe and allowed for a large percentage of complete or partial remissions in 38 patients with MN.